Chromophobe Renal Cell Carcinoma
Watchlist
Retrieved
2022-04-26
Source
Trials
—
Genes
HNF1A,
HNF1B,
TP53,
PTEN,
FLCN,
PIK3CA,
VHL,
ERBB2,
TFE3,
SLC2A1,
KRT7,
PBRM1,
PRCC,
PIDD1,
RYR1,
SFRP2,
RELA,
PVALB,
PTGS2,
ACHE,
BIRC7,
SLC5A3,
MUC4,
LDHB,
AHNAK,
M6PR,
MET,
MITF,
SPTBN4,
NF2
HNF1A,
HNF1B,
TP53,
PTEN,
FLCN,
PIK3CA,
VHL,
ERBB2,
TFE3,
SLC2A1,
KRT7,
PBRM1,
PRCC,
PIDD1,
RYR1,
SFRP2,
RELA,
PVALB,
PTGS2,
ACHE,
BIRC7,
SLC5A3,
MUC4,
LDHB,
AHNAK,
M6PR,
MET,
MITF,
SPTBN4,
NF2,
AP5M1,
OGG1,
PEBP1,
PAK1,
PDHB,
FMN2,
PGK1,
POMC,
ELOC,
SOD2,
ADIPOQ,
PRAME,
SETD2,
SYNE2,
PDXDC1,
RNF139,
AKAP13,
BTG3,
CPQ,
NDRG1,
CUL7,
KEAP1,
ZNF536,
SHANK1,
RPL14,
TET2,
INPP4B,
FPGT,
TNFSF10,
CRADD,
UNC5C,
TAGLN2,
BAP1,
KDM5C,
MLLT10,
LRP1B,
TSC1,
TGM2,
L1CAM,
YIPF3,
PNKD,
KRT32,
SCARB1,
EPAS1,
KRT8,
ASB15,
DNHD1,
EEF2,
FAAH2,
DAPK1,
CTSD,
CTSB,
CRYAB,
CRABP1,
OR4C13,
CNN2,
VMO1,
MSGN1,
ZNF804A,
FAM111B,
CASP2,
CAPG,
BCHE,
APRT,
BIRC5,
APAF1,
ANXA4,
ALOX12B,
ALOX5,
ALK,
ALDH1A1,
ALAD,
ACY1,
CSMD3,
LRRK2,
HSPB1,
GSTT1,
IL13,
IL6R,
IL6,
IL4R,
KCNMA1,
IFNA2,
HSPD1,
FLT1,
HSPA9,
LMAN2L,
HARS1,
CARD11,
GJB1,
GSTP1,
NLRP12,
MTOR,
GSTM1,
SLC49A4,
GRB7,
ZNF765,
NAV3,
HNF1A-AS1,
KIT,
S100A1,
CCND1,
HTC2,
PDCD1LG2,
CD82,
HES4,
CDC73,
ERCC6L,
MIR21,
MIR141,
PSAT1,
SCHIP1,
BHD,
ACAT1,
PROS1,
SMUG1,
SF3B1,
GGT1,
FUT4,
FOLH1,
FOXI1,
ERBB4,
ENPEP,
ELF3,
ELAVL2,
EDNRB,
ACE,
CLDN7,
CP,
CDH16,
CAV1,
CASP3,
KLK3,
ANPEP,
NR3C1,
HIF1A,
HOXA9,
SDHB,
NPEPPS,
NAPSA,
COX5A,
BSND,
TWIST1,
ADAM17,
SLC4A1,
SDC1,
ITGAV,
PLAG1,
SLC26A4,
MST1R,
LGALS3,
LEP,
LAMP1,
KLK2,
CD24
Drugs
(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate,
26 base single stranded phosphodiester DNA oligonucleotide,
4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline
(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate,
26 base single stranded phosphodiester DNA oligonucleotide,
4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline,
Aldesleukin
(
PROLEUKIN
),
Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex
(
ONCOPHAGE
),
Autologous renal cell tumor vaccine,
Axitinib
(
INLYTA
),
Bevacizumab
(
Equidacent,
AVASTIN,
Aybintio,
MVASI
),
Everolimus
(
AFINITOR,
VOTUBIA
),
Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM),
Girentuximab
(
RENCAREX
),
HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMPMMPMUC-RGS),
Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use),
Humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein,
Interferon gamma 1b
(
ACTIMMUNE,
IMUKIN
),
Iodine (131I) chimeric IgG monoclonal antibody cG250,
N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate,
Naptumomab estafenatox,
Pazopanib hydrochloride
(
VOTRIENT
),
Recombinant human interleukin-21,
Recombinant modified vaccinia Ankara expressing human 5T4,
Siltuximab
(
SYLVANT
),
Sorafenib tosylate
(
NEXAVAR
),
Sunitinib malate
(
SUTENT
),
Talactoferrinum alfa,
Temsirolimus
(
TORISEL
)
Registered!
Chromophobe renal cell carcinoma is a rare subtype of the most common form of kidney cancer called renal cell carcinoma (RCC). This type of cancer forms in the cells lining the small tubules in the kidney. These tubules help filter waste from the blood, making urine. Chromophobe RCC accounts for about 5% of all RCC cases, and it is frequently diagnosed between ages 40 and 50. It is typically diagnosed in stage I or stage II, and has an overall better prognosis than other types of RCC. Treatment generally involves surgery.